The growth in the historic period can be attributed to increasing prevalence of chronic migraine conditions, rising diagnosis rates of neurological disorders, growing acceptance of biologic migraine therapies, expansion of specialty neurology clinics, improved access to advanced migraine treatments.
The growth in the forecast period can be attributed to increasing development of next-generation monoclonal antibodies, rising demand for preventive migraine care, expansion of personalized neurology treatment approaches, growing investments in biologic drug pipelines, increasing focus on long-duration migraine therapies. Major trends in the forecast period include increasing adoption of cgrp-targeted migraine therapies, rising use of long-acting preventive migraine treatments, growing focus on biologic-based neurological drugs, expansion of hospital-based infusion therapies, enhanced emphasis on personalized migraine management.
The increasing prevalence of migraines is expected to drive the growth of the Vyepti market in the coming years. Migraines are severe headaches often accompanied by symptoms such as nausea, vomiting, and sensitivity to light or sound. The rising prevalence of migraines is linked to genetic, environmental, and lifestyle factors, including hormonal changes, stress, sleep disturbances, and certain dietary triggers. Vyepti (eptinezumab) treats migraines by targeting and inhibiting the CGRP (calcitonin gene-related peptide) protein, which plays a key role in migraine development, thereby reducing both the frequency and severity of attacks. For instance, in August 2025, according to The Migraine Trust, a UK-based charity, A&E attendance for migraines in England rose by 22% in 2023/2024 compared to the previous year. Therefore, the increasing prevalence of migraines is driving the growth of the Vyepti market.
The increasing healthcare investment and access are expected to support the growth of the Vyepti market. Healthcare investment and access refer to efforts and resources allocated to improve healthcare systems, ensuring timely, affordable, and quality care for populations. Growth in healthcare investment is driven by aging populations, global health challenges, initiatives to reduce health inequities, rising costs, and heightened public awareness. These investments enhance the Vyepti market by improving service quality, fostering innovation, supporting research, and expanding access to advanced migraine therapies. For example, in May 2024, according to the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% growth in 2022. Therefore, rising healthcare investment and access are propelling the Vyepti market.
A key trend in the Vyepti market is the geographic expansion of advanced migraine-preventive therapies into major Asian regions, improving access for underserved patient populations. This trend reflects the growing emphasis on making biologic treatments available in countries with limited preventive migraine options. For instance, in November 2025, H. Lundbeck A/S, a Denmark-based pharmaceutical company, had its new drug application for Vyepti (eptinezumab) accepted by Japan’s Ministry of Health, Labour and Welfare (MHLW), marking a significant step toward its launch in key Asian markets. Vyepti is a humanized monoclonal antibody that targets CGRP, a molecule central to migraine attacks, and is administered intravenously, offering rapid and sustained relief from migraine symptoms.
Major companies operating in the vyepti market are H. Lundbeck A/S.
North America was the largest region in the vyepti market in 2025. The regions covered in the vyepti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vyepti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the vyepti market by increasing costs associated with imported biologic manufacturing inputs, specialized packaging materials, cold-chain logistics components, and infusion-related medical supplies. Healthcare providers in North America and Europe are most affected due to reliance on imported biologics and advanced manufacturing infrastructure, while Asia-Pacific faces higher costs for biologic drug importation. These tariffs contribute to higher treatment costs and reimbursement pressure across hospital pharmacies. However, they are also encouraging localized biologics manufacturing, regional supply chain optimization, and investments in domestic production capabilities to improve long-term treatment accessibility.
The vyepti market research report is one of a series of new reports that provides vyepti market statistics, including vyepti industry global market size, regional shares, competitors with a vyepti market share, detailed vyepti market segments, market trends and opportunities, and any further data you may need to thrive in the vyepti industry. This vyepti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vyepti (eptinezumab-jjmr) is a medication used to prevent chronic migraines in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in transmitting migraine-related pain. Vyepti helps reduce the frequency of migraine attacks and improves quality of life for individuals suffering from chronic migraines.
The primary indications for Vyepti are chronic migraine, episodic migraine, and other neurological conditions. Chronic migraine is a neurological disorder characterized by headaches occurring 15 or more days per month for at least three months, significantly affecting daily life. Vyepti is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving adult and elderly patients.
The vyepti market consists of sales of vyepti injection, IV infusion supplies, sterile accessories, and storage equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing development of next-generation monoclonal antibodies, rising demand for preventive migraine care, expansion of personalized neurology treatment approaches, growing investments in biologic drug pipelines, increasing focus on long-duration migraine therapies. Major trends in the forecast period include increasing adoption of cgrp-targeted migraine therapies, rising use of long-acting preventive migraine treatments, growing focus on biologic-based neurological drugs, expansion of hospital-based infusion therapies, enhanced emphasis on personalized migraine management.
The increasing prevalence of migraines is expected to drive the growth of the Vyepti market in the coming years. Migraines are severe headaches often accompanied by symptoms such as nausea, vomiting, and sensitivity to light or sound. The rising prevalence of migraines is linked to genetic, environmental, and lifestyle factors, including hormonal changes, stress, sleep disturbances, and certain dietary triggers. Vyepti (eptinezumab) treats migraines by targeting and inhibiting the CGRP (calcitonin gene-related peptide) protein, which plays a key role in migraine development, thereby reducing both the frequency and severity of attacks. For instance, in August 2025, according to The Migraine Trust, a UK-based charity, A&E attendance for migraines in England rose by 22% in 2023/2024 compared to the previous year. Therefore, the increasing prevalence of migraines is driving the growth of the Vyepti market.
The increasing healthcare investment and access are expected to support the growth of the Vyepti market. Healthcare investment and access refer to efforts and resources allocated to improve healthcare systems, ensuring timely, affordable, and quality care for populations. Growth in healthcare investment is driven by aging populations, global health challenges, initiatives to reduce health inequities, rising costs, and heightened public awareness. These investments enhance the Vyepti market by improving service quality, fostering innovation, supporting research, and expanding access to advanced migraine therapies. For example, in May 2024, according to the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared to 0.9% growth in 2022. Therefore, rising healthcare investment and access are propelling the Vyepti market.
A key trend in the Vyepti market is the geographic expansion of advanced migraine-preventive therapies into major Asian regions, improving access for underserved patient populations. This trend reflects the growing emphasis on making biologic treatments available in countries with limited preventive migraine options. For instance, in November 2025, H. Lundbeck A/S, a Denmark-based pharmaceutical company, had its new drug application for Vyepti (eptinezumab) accepted by Japan’s Ministry of Health, Labour and Welfare (MHLW), marking a significant step toward its launch in key Asian markets. Vyepti is a humanized monoclonal antibody that targets CGRP, a molecule central to migraine attacks, and is administered intravenously, offering rapid and sustained relief from migraine symptoms.
Major companies operating in the vyepti market are H. Lundbeck A/S.
North America was the largest region in the vyepti market in 2025. The regions covered in the vyepti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vyepti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the vyepti market by increasing costs associated with imported biologic manufacturing inputs, specialized packaging materials, cold-chain logistics components, and infusion-related medical supplies. Healthcare providers in North America and Europe are most affected due to reliance on imported biologics and advanced manufacturing infrastructure, while Asia-Pacific faces higher costs for biologic drug importation. These tariffs contribute to higher treatment costs and reimbursement pressure across hospital pharmacies. However, they are also encouraging localized biologics manufacturing, regional supply chain optimization, and investments in domestic production capabilities to improve long-term treatment accessibility.
The vyepti market research report is one of a series of new reports that provides vyepti market statistics, including vyepti industry global market size, regional shares, competitors with a vyepti market share, detailed vyepti market segments, market trends and opportunities, and any further data you may need to thrive in the vyepti industry. This vyepti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vyepti (eptinezumab-jjmr) is a medication used to prevent chronic migraines in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in transmitting migraine-related pain. Vyepti helps reduce the frequency of migraine attacks and improves quality of life for individuals suffering from chronic migraines.
The primary indications for Vyepti are chronic migraine, episodic migraine, and other neurological conditions. Chronic migraine is a neurological disorder characterized by headaches occurring 15 or more days per month for at least three months, significantly affecting daily life. Vyepti is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving adult and elderly patients.
The vyepti market consists of sales of vyepti injection, IV infusion supplies, sterile accessories, and storage equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Vyepti Market Characteristics
3. Vyepti Market Supply Chain Analysis
4. Global Vyepti Market Trends and Strategies
5. Vyepti Market Analysis of End Use Industries
7. Global Vyepti Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Vyepti Total Addressable Market (TAM) Analysis for the Market
9. Vyepti Market Segmentation
10. Vyepti Market Regional and Country Analysis
11. Asia-Pacific Vyepti Market
12. China Vyepti Market
13. India Vyepti Market
14. Japan Vyepti Market
15. Australia Vyepti Market
16. South Korea Vyepti Market
17. Western Europe Vyepti Market
18. UK Vyepti Market
19. Germany Vyepti Market
20. France Vyepti Market
21. Eastern Europe Vyepti Market
22. North America Vyepti Market
23. USA Vyepti Market
24. Canada Vyepti Market
25. South America Vyepti Market
26. Middle East Vyepti Market
27. Africa Vyepti Market
29. Vyepti Market Competitive Landscape and Company Profiles
32. Vyepti Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Vyepti Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses vyepti market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vyepti? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vyepti market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Chronic Migraine; Episodic Migraine; Other Neurological Indications2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Companies Mentioned: H. Lundbeck A/S.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Vyepti market report include:- H. Lundbeck A/S.
